Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amivantamab + paclitaxel
- Development stage
- Phase 2
- Lead developer
- Johnson & Johnson
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**Amivantamab + paclitaxel** is a combination therapeutic regimen being studied for use in recurrent or metastatic cancers, primarily head and neck squamous cell carcinoma and non-small cell lung cancer. - **Amivantamab** is a bispecific monoclonal antibody that targets both epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET), designed to block the ligand binding and induce antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing these receptors. - **Paclitaxel** is a chemotherapeutic agent of the taxane class that stabilizes microtubules and inhibits their depolymerization, thereby disrupting cell division and inducing cell death in rapidly proliferating tumor cells. Combining amivantamab with paclitaxel aims to exploit the synergistic potential of targeted therapy (amivantamab) and cytotoxic chemotherapy (paclitaxel) for enhanced antitumor efficacy. Current ongoing clinical trials are investigating its safety, tolerability, and clinical activity in platinum-naïve recurrent or metastatic head and neck squamous cell carcinoma, among other cancers[1][3].
- Other names
- amivantamab + paclitaxel
02
Targets
EGFR (Epidermal growth factor receptor)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)MET (Mesenchymal-epithelial transition factor receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on amivantamab + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amivantamab + paclitaxel.